Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner’s syndrome: report of two cases
© The Author(s). 2016
Received: 3 February 2016
Published: 4 July 2016
A minority of intra-abdominal desmoid tumors is associated with Gardner’s syndrome in which desmoid tumors become an important cause of morbidity and mortality if they are surgically unresectable.
Here, we report two cases of intestinal perforation during chemotherapy in patients with Gardner’s syndrome-associated intra-abdominal desmoids. One female and one male patients who developed inoperable desmoids were given the chemotherapeutic regimen of doxorubicin plus dacarbazine, followed by meloxicam. Significant tumor regression was observed clinically. However, intestinal perforation happened in both patients. They were subjected to emergency surgery, follow-up management, and survived up to now.
The doxorubicin plus dacarbazine chemotherapy is an effective treatment for intra-abdominal demoid tumors in patients with Gardner’s syndrome. On the other hand, given severe adverse events might occur, clinicians should pay more attention that tumor quick regression may cause intestinal perforation in which urgent surgical intervention is necessary.
Desmoid tumors (aggressive fibromatosis) are rare, locally aggressive, benign fibroblastic tumors, accounting for ~0.03 % of all neoplasms. Although desmoid tumors (DTs) are histologically benign and without any metastatic potential, they are locally aggressive with a tendency to invade nearby structures and recur after resection. The etiology of these tumors is still controversial, but antecedent trauma including surgery, endocrine, and genetic factors seem to be implicated. Most desmoids are sporadic, but some are in association with familial adenomatous polyposis (FAP), also known as Gardner’s syndrome.
Although desmoid tumors can arise at any body site, the desmoids in Gardner’s syndrome usually arise in the abdomen and are a major cause of morbidity and mortality in patients who undergone prophylactic colonic surgery [1, 2]. Desmoids account for 10–14 % of deaths of Gardner’s syndrome patients due to intestinal obstruction or perforation, making it the second leading cause of death after colorectal carcinoma [3, 4]. Complete surgical removal remains the optimal treatment for extra-abdominal and abdominal-wall desmoids but is not recommended for mesenteric desmoids because of the high risk of recurrence and the difficulties involved in the operation . Besides, surgical excision of intra-abdominal desmoids is hazardous, with a perioperative mortality rate of 10 to 60 % and can lead to further tumor progression [6, 7]. Nonoperative therapies include antiestrogen, nonsteroidal anti-inflammatory drugs, chemotherapy, and targeted therapy. Here, we evaluate the efficacy of a combination therapy of doxorubicin (DOX) plus dacarbazine (DTIC), and meloxicam, which was shown effective in patients with Gardner’s syndrome not amenable to surgery [8–10].
Multidisciplinary team (MDT) discussion indicated that the tumors were unresectable. On Oct 11th 2012, the patient was administrated with systemic chemotherapy: doxorubicin (20 mg/m2 daily) plus DTIC (150 mg/m2 daily) throughout 4 days of drip intravenous infusion every 28 days, followed by meloxicam (10 mg/m2). The abdominal bloating was relieved after 1 cycle of chemotherapy. At the end of the second cycle of chemotherapy, the patient felt abdominal pain and fever. X-ray imaging displayed a little shadow of free gas below the right diaphragm (Fig 1b). Blood test showed WBC 22.6 × 109/L, N 89 %. The evidence indicated bowel perforation. Benefit from the tumor shrinkage, intestinal anastomosis and right lower abdominal colostomy were successfully performed. The patient was administrated with meloxicam (7.5 mg bid) after the operation. The lesion remains without tumor progression till now (Fig 1c, more than 40 months so far).
About 10 % of Gardner’s syndrome patients develop mesenteric desmoids . In contrast to sporadic DTs, the majority of tumors in patients with Gardner’s syndrome present intra-abdominally. Surgery is the widely accepted first-line treatment for extra-abdominal and abdominal-wall desmoids but is not recommended for intra-abdominal desmoids given the operational difficulties and high risk of recurrence [12, 13]. American Society of Colon and Rectal Surgeons therefore advocate conservative management over initial resection for patients with Gardner’s syndrome or with large slowly growing desmoids compromising the mesentery, vessels, or adjacent organs [14, 15]. Both our patients developed desmoid tumors after prophylactic colectomy of Gardner’s syndrome and presented with abdominal symptoms caused by the compression of the huge mass, indicating a demand for clinical intervention.
Choosing optimal therapy for patients with Gardner’s syndrome is difficult because the diagnosis is rare and no randomized and prospective trials for different treatment approaches are available. In addition, the evaluation of efficacy is problematic given that desmoids have a variable natural history, with some tumors showing spontaneous regression in the absence of treatment. Therefore, the treatment plans have to consider that the growth of DT can be highly variable with growing, stabilization, and even regression. Nonsteroidal anti-inflammatory drugs (NSAIDs) and antiestrogens may be used as first-line therapies for an unresectable tumor . However, NSAIDs and hormone therapy have shown limited success in intra-abdominal desmoids [17, 18]. Cytotoxic chemotherapy is recently investigated for treating such cases. It has been reported that cytotoxic-chemotherapy benefits about 20 to 75 % of treated desmoid patients . Several studies indicated the efficacy and safety of the chemotherapy regimen of doxorubicin and dacarbazine combination in treating patients with Gardner’s syndrome-associated desmoid tumors [8, 9, 20, 21]. Gega combined DOX, DTIC, and meloxicam in the treatment of Gardner’s syndrome-associated desmoids and achieved a great success with high rates of partial or complete response . Adapted the regimen applied by Gega in our study, we observed the remission of symptom in patient 1 and significant tumor shrinkage (partial response) in patient 2, which supports the efficacy of this modality. Unexpectedly, bowel perforation happened in both patients during the treatment. Postoperative pathology analyses showed necrosis of the desmoids. To our knowledge, this is the first time to report such a drastic adverse event resulting from DOX-DTIC-meloxicam in the treatment of Gardner’s syndrome-associated desmoids. It is likely due to the sensitivity to chemotherapy and acute necrosis of the desmoids as indicated by significant tumor regression. Fortunately, we were able to perform intestinal anastomosis in time by the support of MDT. Patients recovered well from the surgery and won the opportunity for further therapy. Inhibited by chemotherapy, the fast growing tumor became amenable to palliative surgery and the residual tumor could be controlled by NASIDs. Alternatively, we speculate that reduction of the dosage may eliminate the adverse effect of DOX-DTIC-meloxicam. In fact, Yamaoto employed low-dose DOX-DTIC therapy to three patients against intra-abdominal desmoids, which was a safe and effective regimen and permitted repeated administration cycles (50 mg/m2 DOX and 600–700 mg/m2 DTIC per cycle) up to 10–11 times .
In conclusion, we reported two cases of unresectable intra-abdominal desmoid tumors associated with Gardner’s syndrome. Our study provides further evidence of the remarkable efficacy of the DOX-DTIC regimen. However, the drastic regression of tumor upon DOX-DTIC treatment resulted in the perforation of implicated intestine. Even if there is no evidence of intestinal perforation in X-ray imaging during the management of intra-abdominal desmoids complicating Gardner’s syndrome, oncologists should be aware of the possibility of perforation when the patients have high fever and abdominal pain. MDT discussion and team work may be helpful. The modality of DOX-DTIC-meloxicam requires further study on a clinical trial basis. We are also trying a sequential chemotherapeutic regimen of DTIC followed by doxorubicin plus NASID. New results are expected in the near future.
DOX, doxorubicin; DTIC, dacarbazine; DTs, desmoid tumors; FAP, familial adenomatous polyposis; MDT, multidisciplinary team; NSAIDs, nonsteroidal anti-inflammatory drugs
There is no funding support for this study.
Availability of data and material
Materials described in the manuscript could be shared freely to any scientist wishing to use them, without breaching participant confidentiality.
YZ, WL, QL, HT, and WL treated the patient clinically. WL drafted the manuscript. YZ contributed to the critical revisions and intellectual content. All authors read and approved the final manuscript. The study was conducted without any funding support.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patients for publication of the Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
The report was approved by the relevant institutional review board or ethics committee of Zhongshan Hospital Fudan University. The approval number is B2012-022.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, Pierotti M, Spinelli P, Radice P. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 2003;21:1698–707.View ArticlePubMedGoogle Scholar
- Hartley JE, Church JM, Gupta S, McGannon E, Fazio VW. Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum. 2004;47:334–40.View ArticlePubMedGoogle Scholar
- Turina M, Pavlik CM, Heinimann K, Behrensmeier F, Simmen HP. Recurrent desmoids determine outcome in patients with Gardner syndrome: a cohort study of three generations of an APC mutation-positive family across 30 years. Int J Colorectal Dis. 2013;28:865–72.View ArticlePubMedGoogle Scholar
- Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, Kerr MC, Hamilton SR. Desmoid tumours in familial adenomatous polyposis. Gut. 1994;35:377–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.PubMedGoogle Scholar
- Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG 3rd, Gamblin TC, Pawlik TM. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19:4036–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Shapeero LG, De Visschere PJ, Verstraete KL, Poffyn B, Forsyth R, Sys G, Uyttendaele D. Post-treatment complications of soft tissue tumours. Eur J Radiol. 2009;69:209–21.View ArticlePubMedGoogle Scholar
- Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, Oshima T, Fujiwara Y, Gondo N, Tamura K, Utsunomiya J, Hashimoto-Tamaoki T, Yamamura T. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 2006;24:102–5.View ArticlePubMedGoogle Scholar
- Lynch HT, Fitzgibbons R, Jr., Chong S, Cavalieri J, Lynch J, Wallace F, Patel S. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner’s syndrome. Dis Colon Rectum. 1994;37:260–7.View ArticlePubMedGoogle Scholar
- Garbay D, Le Cesne A, Penel N, Chevreau C, Marec-Berard P, Blay JY, Debled M, Isambert N, Thyss A, Bompas E, Collard O, Salas S, Coindre JM, Bui B, Italiano A. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.View ArticlePubMedGoogle Scholar
- Escobar C, Munker R, Thomas JO, Li BD, Burton GV. Update on desmoid tumors. Ann Oncol. 2011;23:562–9.View ArticlePubMedGoogle Scholar
- Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999;86:1185–9.View ArticlePubMedGoogle Scholar
- Pinheiro LV, Fagundes JJ, Coy CS, Cabello C, Toro I, Michellino M, Fachina PH, Ward M, Leal RF, Ayrizono Mde L. Multiple desmoid tumors in a patient with Gardner’s syndrome—report of a case. Int J Surg Case Rep. 2014;5:370–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux C, Casali PG, Le Cesne A, Gronchi A, Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.View ArticlePubMedGoogle Scholar
- Seow-Choen F. The management of desmoids in patients with familial adenomatous polyposis (Gardner’s syndrome). Acta Chir Iugosl. 2008;55:83–7.View ArticlePubMedGoogle Scholar
- Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100:612–20.View ArticlePubMedGoogle Scholar
- Berk T, Cohen Z, McLeod RS, Stern HS. Management of mesenteric desmoid tumours in familial adenomatous polyposis. Can J Surg. 1992;35:393–5.PubMedGoogle Scholar
- Soravia C, Sugg SL, Berk T, Mitri A, Cheng H, Gallinger S, Cohen Z, Asa SL, Bapat BV. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Pathol. 1999;154:127–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14:181–90.View ArticlePubMedGoogle Scholar
- Ezumi K, Yamamoto H, Takemasa I, Nomura M, Ikeda M, Sekimoto M, Monden M. Dacarbazine-doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. Jpn J Clin Oncol. 2008;38:222–6.View ArticlePubMedGoogle Scholar
- Yamamoto H, Oshiro R, Nishimura J, Uemura M, Haraguchi N, Hata T, Takemasa I, Mizushima T, Sekimoto M, Doki Y, Mori M. Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. Oncol Rep. 2013;29:1751–5.PubMedGoogle Scholar